Human papillomavirus vaccine recombinant quadrivalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Merck

Alternative Names: Gardasil; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Merck; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Merck; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Merck; q HPV; Quadrivalent human papillomavirus vaccine - Merck; Silgard; V 501

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CSL; The University of Queensland
  • Developer Banyu; CSL; Merck & Co; Merck Sharp & Dohme; University of California at San Francisco
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Gynaecological cancer; Human papillomavirus infections
  • Phase III Condylomata acuminata; Penile cancer

Most Recent Events

  • 30 Aug 2017 Merck & Co completes a phase III trial for prevention of Human papilloma virus infection, Anal cancer, Anal intraepithelial neoplasia and Condylomata acuminata (In adolescents, In adults) in Japan (IM) (NCT01862874)
  • 03 Apr 2017 Merck completes a phase III trial in Anal intraepithelial neoplasia (Prevention) in USA, Australia, Brazil, Canada, Costa Rica, Finland, Mexico, Netherlands, Norway, Peru, Philippines, Portugal, South Africa, Sweden, Spain, Germany and Taiwan (IM) (NCT00090285)
  • 16 Jan 2017 Merck initiates enrolment in a phase II trial for Human papillomavirus infections (Prevention) in Australia (IM) (NCT03000933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top